Biotest AG
BIO3 | F
Overview
Corporate Details
- ISIN(s):
- DE0005227201 (+1 more)
- LEI:
- 529900JVX7RPXBLYUD89
- Country:
- Germany
- Address:
- Landsteinerstraße 5, 63303 Dreieich
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Our products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine. For patients with serious and often chronic diseases they provide targeted treatment, which generally enable them to lead almost normal lives. Within our areas of specialisation, we start from pre-clinical and clinical development to manufacturing and global marketing. Research, development and production are carried out at our main headquarters in Germany. Our own sales organisations (subsidiaries) and cooperating partners represent our global distribution network.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-23 17:03 |
Regulatory News Service
Biotests positive fibrinogen phase III trial results published in The Lancets e…
|
English | 14.5 KB | |
| 2025-06-20 00:00 |
Regulatory News Service
Berichtigung der Veröffentlichung vom 17.04.2025
|
German | 303.6 KB | |
| 2025-06-03 16:51 |
Delisting Announcement
Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with …
|
English | 8.2 KB | |
| 2025-05-28 17:00 |
Board/Management Change
Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
|
English | 8.1 KB | |
| 2025-05-12 17:35 |
Earnings Release
Biotest confirms Guidance for 2025
|
English | 11.5 KB | |
| 2025-05-12 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2025
|
English | 414.7 KB | |
| 2025-05-05 00:00 |
Sustainability Report
Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage de…
|
German | 11.9 KB | |
| 2025-04-16 00:00 |
Regulatory News Service
Berichtigt am 17.06.2025
|
German | 424.7 KB | |
| 2025-03-31 07:00 |
Earnings Release
Biotest AG increases sales by 6% in financial year 2024
|
English | 13.8 KB | |
| 2025-03-31 00:00 |
Annual Report
Annual financial report 2024
|
English | 3.0 MB | |
| 2025-03-06 09:01 |
Board/Management Change
Biotest AG: CFO Martin Moller to leave Biotest as planned at the end of his con…
|
English | 8.9 KB | |
| 2025-02-28 20:50 |
Report Publication Announcement
|
English | 5.9 KB | |
| 2025-02-27 18:22 |
Earnings Release
Biotest AG publishes preliminary business figures - 2024 forecasts partially ex…
|
English | 9.4 KB | |
| 2025-02-27 00:00 |
Regulatory News Service
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
|
German | 5.8 KB | |
| 2025-02-27 00:00 |
Regulatory News Service
Hinweis auf Konzernabschluss vom 01.01.2024 bis zum 31.12.2024
|
English | 5.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-29 | Bernöster, Dr. Katrin | Other | Sell | None | 15,640.00 EUR |
| 2021-11-29 | Realsoul Holding S.A. | Close relation | Buy | None | 1,713.60 EUR |
| 2021-11-18 | Fleck, Stephan | Other | Sell | None | 120,870.00 EUR |
| 2021-11-18 | Schüttrumpf, Dr. Jörg | Other | Sell | None | 99,895.50 EUR |
| 2021-11-18 | Reinecke, Dr. Martin | Other | Sell | None | 37,715.00 EUR |
| 2021-11-18 | Moritz, Michael | Other | Sell | None | 35,460.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nattaro Labs AB | Sweden | NATTA | |
|
Neovacs | France | ALNEV | |
|
Newron Pharmaceuticals S.p.A. | Italy | NWRN | |
|
NextCell Pharma AB | Sweden | NXTCL | |
|
NextFerm Technologies Ltd. | Israel | NXFR | |
|
NFL Biosciences | France | ALNFL | |
|
Nortem BioGroup | Spain | MLBIO | |
|
Novo Nordisk | Denmark | NOVO | |
|
NRGene Technologies Ltd. | Israel | NRGN | |
|
NUFORMIX PLC | United Kingdom | NFX |